Blood test guides new combo therapy for tough lung cancer
NCT ID NCT07410611
Summary
This study is testing if a targeted drug called befotertinib, when combined with radiation, can better control a specific type of advanced lung cancer that has spread to only a few places. It will enroll 84 adults with a certain genetic change (EGFR mutation) in their cancer. Doctors will use regular blood tests to monitor tiny bits of cancer DNA and guide the treatment plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE TESTED POSITIVE FOR EGFR MUTATIONS CONFIRMED BY HISTOPATHOLOGICAL EXAMINATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.